Alzamend Neuro, Inc.
ALZNDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
AL001
Alzheimer's Disease
ALZN002 (autologous DCs pulsed with E22W mutant peptide).
Alzheimer Disease
Lithium carbonate
Bipolar I Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AL001 | Phase 2 | Alzheimer's Disease | - | - |
ALZN002 (autologous DCs pulsed with E22W mutant peptide). | Phase 2 | Alzheimer Disease | - | - |
Lithium carbonate | Phase 2 | Bipolar I Disorder | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Alzamend Neuro, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Alzamend Neuro, Inc.'s (ALZN) pipeline across Phase 2. Its lead program is AL001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alzamend Neuro, Inc.'s next FDA catalyst?→
Alzamend Neuro, Inc.'s (ALZN) next tracked catalyst is a Phase 2 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALZN biotech catalysts?→
Add ALZN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alzamend Neuro, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.